1. Home
  2. YARW

as of 08-28-2026 3:59pm EST

$37.00
$1.00
-2.63%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.

Founded: N/A Country:
United States
United States
Employees: N/A City: BRIDGEWATER
Market Cap: 114.6M IPO Year: 2017
Target Price: N/A AVG Volume (30 days): 25.9K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -7.68 EPS Growth: 33.33
52 Week Low/High: $31.55 - $44.28 Next Earning Date: N/A
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A
P/E Ratio: -4.95 Index: N/A
Free Cash Flow: -33124000.0 FCF Growth: N/A

Earnings Transcripts

SEC 8-K filings with transcript text

View All
2026
Q2

Q2 2026 Earnings

8-K/A

Aug 13, 2026

0001104659-26-095925

Transcript text not available. View on SEC.gov →

Share on Social Networks: